Bioanalytical Track

Beyond the Analysis: Immunogenicity and Beyond

Moderator(s)

• 

  Mark Wissel, PhD

  Director Research and Development
  Eurofins Viracor BioPharma Services
  Lenexa, Kansas

Presentations:

• 8:05 AM - 8:35 AM ET

  Evaluating the Immunogenicity of Peptides form the Clinical Pharmacology Perspective
  

  Speaker: Mohsen Rajabi, PhD – Novartis
• 8:35 AM - 9:05 AM ET

  Systematic Assessment of S/N Ratios as Alternative for ADA Titers
  

  Speaker: HISANORI HARA, MSc – B2S Life Sciences
• 9:05 AM - 9:35 AM ET

  Bioanalytical Approaches for Assessing the Immunogenicity of RNA Therapeutics
  

  Speaker: Lynn Kamen, PhD – BioAgilytix
• 10:05 AM - 10:35 AM ET

  Insights into Non-Bridging Assay Designs for Detection of Anti-Drug Antibodies
  

  Speaker: Ronald R. Bowsher, PhD, FAAPS – B2S Life Sciences
• 10:35 AM - 11:05 AM ET

  ADA Interference for a Ligand Binding Drug Concentration Assay
  

  Speaker: Karen Liao, MD – Merck
• 11:05 AM - 11:55 AM ET

  Beyond the Analysis: Immunogenicity and Beyond: Panel Discussion
  

  Moderator: Mark Wissel, PhD – Eurofins Viracor BioPharma Services

  Speaker: HISANORI HARA, MSc – B2S Life Sciences

  Speaker: Karen Liao, MD – Merck

  Speaker: Ronald R. Bowsher, PhD, FAAPS – B2S Life Sciences

  Speaker: Mohsen Rajabi, PhD – Novartis

  Speaker: Lynn Kamen, PhD – BioAgilytix
• 11:55 AM - 12:00 PM ET

  Closing Remarks
  

  Moderator: Mark Wissel, PhD – Eurofins Viracor BioPharma Services